DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Male Hypogonadism - Pipeline Review, H1 2017" report to their offering.

The latest Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 1, 4, 7, 2, 1 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

For more information about this report visit https://www.researchandmarkets.com/research/gxm3xp/male_hypogonadism

The rest is here:
Male Hypogonadism Pipeline Report, H1 2017 - Therapeutics Review of 15 Companies & Drug Profiles - Research ... - Business Wire (press release)

Comments are closed.